O&D Bio

O&D Bio is a South Korean biotechnology company dedicated to the discovery and development of innovative small molecule therapeutics for inflammatory and autoimmune disorders. Founded in 2020, the company specializes in targeting the Salt-Inducible Kinase 2 (SIK2) and the NLRP3 inflammasome pathways to address significant unmet medical needs in chronic conditions. Its lead pipeline candidate, ODB-101, is a topical SIK2 inhibitor currently in pre-clinical development for atopic dermatitis, designed to offer a safer and more effective alternative to existing steroid treatments. Additionally, O&D Bio is advancing candidates for other chronic conditions including psoriasis, inflammatory bowel disease, and NASH. The company leverages its proprietary medicinal chemistry expertise to optimize drug candidates for high potency and selectivity. Backed by prominent venture capital firms, O&D Bio continues to expand its research capabilities and therapeutic reach within the immunology space.